Burrill Report: Leading Malaria Drug Becoming Less Effective
Poor regulations and substandard use could be to blame for growing resistance to a leading anti-malaria drug, researchers say.
Articles by vanderson
FDA Approves First Monthly Atypical Antipsychotic for Schizophrenia
The U.S. Food and Drug Administration has approved Janssen Pharmaceuticals’ Invega Sustenna for acute and maintenance treatment of schizophrenia.
Bioheart Gets the Go-Ahead for Clinical Trial of Heart Failure Therapy
Bioheart, a developer of cell-based therapies for cardiovascular diseases, has been granted FDA approval to proceed with a Phase I clinical trial for a potential congestive heart failure treatment.
DATATRAK Awarded Phase III Trial With Top 20 Pharma Company
DATATRAK International, a provider of technical support systems for clinical studies, has been awarded a Phase III clinical trial by the European division of a Global Top 20 pharmaceutical company.
MuGard: Potential Blockbuster for Oral Mucositis Prevention Market
Oral mucositis is a nearly inevitable complication for patients undergoing chemotherapy or radiation treatment for head or neck cancer.
OneMedPlace Partners With Two Television Programs
The Art of Living with Marilu Henner and Inside Business with Fred Thompson have entered into a strategic partnership with OneMedPlace to provide a multi-platform distribution pipeline for quality, educational television programming.
GSK and Enigma Pair Up to Develop Influenza Diagnostics
The new test would analyze swab samples and return a diagnosis in less than 60 minutes.
Wireless Pacemakers Approved for Patient Use
With the U.S. approval of two new wireless devices from St. Jude Medical, pacemaker users may no longer have to go to the doctor for follow-up visits.
Biotech Industry Tops for Venture Capital Investors
A new report published by PricewaterhouseCoopers and the National Venture Capital Association found that life sciences companies garnered the most investment dollars out of any industry in the second quarter of 2009.
Human Genome’s Lupus Drug Surprises Analysts
Shares in Human Genome Sciences increased by 277 percent on Monday after the company announced that their lupus drug Benlysta succeeded in a Phase III clinical trial.